Last updated on July 2019

Efficacy and Safety Study of Tenalisib (RP6530) a Novel PI3K / Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)


Brief description of study

To assess the anti-tumor activity and safety of Tenalisib in patients with relapsed/refractory indolent Non-Hodgkin's Lymphoma (iNHL),

Clinical Study Identifier: NCT03711578

Find a site near you

Start Over